Skip to content

Study · Non-randomized trial · n = 7 · 1986

2 results

Cholinergic mediation in dermorphin-induced growth hormone secretion in man.

degli Uberti EC, Trasforini G, Salvadori S, Margutti A, Bianconi M, Teodori V, Tomatis R, Pansini R

Hormone research1 Jan 1986Cited by 1 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy men, dermorphin elevated GH levels.

    In plain wordsIn healthy men, dermorphin increased growth hormone levels.

    Peptide
    Dermorphin
    Outcome
    IncreaseGH levels
    Study

    n = 7

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    D produced clear elevations in GH and PRL levels.
    1 context sentence
    Summary · context
    The effects of pirenzepine (P), a cholinergic muscarinic antagonist, on growth hormone (GH) and prolactin (PRL) response to dermorphin (D) were studied in a group of 7 healthy men.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy men, dermorphin elevated PRL levels.

    In plain wordsIn healthy men, dermorphin increased prolactin levels.

    Peptide
    Dermorphin
    Outcome
    IncreasePRL levels
    Study

    n = 7

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    D produced clear elevations in GH and PRL levels.
    1 context sentence
    Summary · context
    The effects of pirenzepine (P), a cholinergic muscarinic antagonist, on growth hormone (GH) and prolactin (PRL) response to dermorphin (D) were studied in a group of 7 healthy men.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.